Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
| Preferred Name | Trastuzumab | |
| Synonyms |
|
|
| Definitions |
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1647 |
|
| Accepted_Therapeutic_Use_For |
Breast cancer overexpressing HER2 protein; Pancreatic cancer overexpressing p185HER2
|
|
| ALT_DEFINITION |
A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Trastuzumab binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Trastuzumab is a type of monoclonal antibody and a type of HER2 receptor antagonist.
|
|
| CAS_Registry |
180288-69-1
|
|
| code |
C1647
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
|
|
| Display_Name |
Trastuzumab
|
|
| FDA_UNII_Code |
P188ANX8CK
|
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Trastuzumab
|
|
| Legacy Concept Name |
Trastuzumab
|
|
| Maps_To |
Trastuzumab
|
|
| NCI_Drug_Dictionary_ID |
42265
|
|
| NSC Number |
688097
|
|
| PDQ_Closed_Trial_Search_ID |
42265
|
|
| PDQ_Open_Trial_Search_ID |
42265
|
|
| Preferred_Name |
Trastuzumab
|
|
| prefixIRI |
NCIT:C1647
|
|
| prefLabel |
Trastuzumab
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor
|
|
| UMLS_CUI |
C0728747
|
|
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping